Tandem unveils free software update for predictive glucose tracking and insulin delivery

person in kayak holding Tandem insulin pump in one hand, screen says bolus initiated
The updated algorithms aim to predict trends in glucose and suspend insulin delivery when low levels are anticipated. (Tandem Diabetes Care)

Tandem Diabetes Care launched a new predictive feature designed to help reduce the frequency and duration of low-glucose events by pausing insulin delivery. The technology is available as a free software update for its t:slim X2 insulin pumps using the Dexcom G6 continuous glucose monitoring system.

Pumps preloaded with the new technology, titled Basal-IQ, are expected to begin shipping by the end of the month, the San Diego, California-based company said. The software update will require a new prescription and completion of a 45-minute online training module, both coordinated through an online portal.

The Basal-IQ algorithms are designed to predict trends in glucose levels up to 30 minutes ahead, suspending insulin when low levels are anticipated, and automatically resuming when glucose numbers begin to rise.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“This launch marks the achievement of our goal to offer people with diabetes a simple-to-use automated insulin delivery feature that can reduce time spent low without adding significant burden to the pump therapy experience,” Tandem’s president and CEO, Kim Blickenstaff, said in a statement.

In a clinical study, Basal-IQ demonstrated a 31% reduction in time spent below 70 mg/dL, with no rebound hyperglycemia compared to a CGM-enabled insulin pump without the feature, Tandem said.

RELATED: FDA approves Tandem’s insulin pump with Dexcom CGM integration

Tandem first received FDA approval in August of last year for its touchscreen insulin pump, using Dexcom’s G5 CGM platform, which allowed patients to make treatment decisions without pricking their finger. At the time, Tandem rolled out a remote software update to users to allow them to view insulin delivery activity alongside CGM data from the implanted Dexcom sensor on the t:slim X2’s screen.

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.